MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317355 | Name: Bumetanide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in people in whom high doses of furosemide are ineffective. It is marketed by Hoffmann-La Roche. The main difference between the two substances is in bioavailability and pharmacodynamic potency. Furosemide is incompletely absorbed in the intestine (60%), and there are substantial inter- and intraindividual differences in bioavailability (range 10-90%). Bumetanide is almost completely absorbed (80%), and the absorption is not altered when it is taken with food. It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect.

Chemical Structure

Bumetanide
Bumetanide
CAS#28395-03-1

Theoretical Analysis

MedKoo Cat#: 317355

Name: Bumetanide

CAS#: 28395-03-1

Chemical Formula: C17H20N2O5S

Exact Mass: 364.1093

Molecular Weight: 364.42

Elemental Analysis: C, 56.03; H, 5.53; N, 7.69; O, 21.95; S, 8.80

Price and Availability

Size Price Availability Quantity
500mg USD 200.00 2 Weeks
1g USD 350.00 2 Weeks
2g USD 550.00 2 Weeks
5g USD 950.00 2 Weeks
10g USD 1,350.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Bumetanide, Trade names: Bumex or Burinex; PF 1593, PF-1593, PF1593; Ro 10-6338; Ro10-6338
IUPAC/Chemical Name
3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
InChi Key
MAEIEVLCKWDQJH-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)
SMILES Code
O=C(O)C1=CC(S(=O)(N)=O)=C(OC2=CC=CC=C2)C(NCCCC)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Bumetanide (Ro 10-6338; PF 1593), a highly potent loop diuretic, is a Na+-K+-Cl+ cotransporter (NKCC) blocker.
In vitro activity:
The addition of bumetanide (20μM) to the culture medium prevented the ethanol-induced escalation of Nkx2.1+ interneuron migration into the cortex with no significant difference observed compared to control (Figure 3a and b; EtOH+Bumet x− = 61.1 ± 2.4 cells, 10 cultures; P > 0.999; effect size ω2 for treatment = 0.23). Reference: eLife. 2019; 8: e48648. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768659/
In vivo activity:
This study further found that the decrease in head-dipping behavior caused by diazepam was blocked by bumetanide, a Na+-K+-2Cl- cotransporter isoform 1 (NKCC1) antagonist, in LPS-treated mice. Reference: Eur J Pharmacol. 2021 Aug 5;904:174195. https://pubmed.ncbi.nlm.nih.gov/34004209/
Solvent mg/mL mM
Solubility
DMSO 53.8 147.66
DMF 33.0 90.56
DMF:PBS (pH 7.2) (1:1) 0.5 1.37
Ethanol 20.7 56.72
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 364.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Skorput AG, Lee SM, Yeh PW, Yeh HH. The NKCC1 antagonist bumetanide mitigates interneuronopathy associated with ethanol exposure in utero. Elife. 2019 Sep 23;8:e48648. doi: 10.7554/eLife.48648. PMID: 31545168; PMCID: PMC6768659. 2. Dzhala V, Staley KJ. Acute and chronic efficacy of bumetanide in an in vitro model of posttraumatic epileptogenesis. CNS Neurosci Ther. 2015 Feb;21(2):173-80. doi: 10.1111/cns.12369. Epub 2014 Dec 12. PMID: 25495911; PMCID: PMC4391014. 3. Matsumoto D, Ushio S, Wada Y, Noda Y, Esumi S, Izushi Y, Kitamura Y, Sendo T. Bumetanide prevents diazepam-modified anxiety-like behavior in lipopolysaccharide-treated mice. Eur J Pharmacol. 2021 Aug 5;904:174195. doi: 10.1016/j.ejphar.2021.174195. Epub 2021 May 15. PMID: 34004209. 4. Palaniappan B, Solomon AP, C DR. Targeting AgrA quorum sensing regulator by bumetanide attenuates virulence in Staphylococcus aureus - A drug repurposing approach. Life Sci. 2021 May 15;273:119306. doi: 10.1016/j.lfs.2021.119306. Epub 2021 Mar 1. PMID: 33662434.
In vitro protocol:
1. Skorput AG, Lee SM, Yeh PW, Yeh HH. The NKCC1 antagonist bumetanide mitigates interneuronopathy associated with ethanol exposure in utero. Elife. 2019 Sep 23;8:e48648. doi: 10.7554/eLife.48648. PMID: 31545168; PMCID: PMC6768659. 2. Dzhala V, Staley KJ. Acute and chronic efficacy of bumetanide in an in vitro model of posttraumatic epileptogenesis. CNS Neurosci Ther. 2015 Feb;21(2):173-80. doi: 10.1111/cns.12369. Epub 2014 Dec 12. PMID: 25495911; PMCID: PMC4391014.
In vivo protocol:
1. Matsumoto D, Ushio S, Wada Y, Noda Y, Esumi S, Izushi Y, Kitamura Y, Sendo T. Bumetanide prevents diazepam-modified anxiety-like behavior in lipopolysaccharide-treated mice. Eur J Pharmacol. 2021 Aug 5;904:174195. doi: 10.1016/j.ejphar.2021.174195. Epub 2021 May 15. PMID: 34004209. 2. Palaniappan B, Solomon AP, C DR. Targeting AgrA quorum sensing regulator by bumetanide attenuates virulence in Staphylococcus aureus - A drug repurposing approach. Life Sci. 2021 May 15;273:119306. doi: 10.1016/j.lfs.2021.119306. Epub 2021 Mar 1. PMID: 33662434.
1: Geng H, Li B, Song X, Xia Y, Zhou X, Gao J, Chen L. 抑制NKCC1/AQP4通路对改善高原脑水肿大鼠神经损伤的作用 [Effects of Inhibiting the NKCC1/AQP4 Pathway on Neurological Injury Improvement in a Rat Model of High-Altitude Cerebral Edema]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2025 Jan 20;56(1):156-165. Chinese. doi: 10.12182/20250160204. PMID: 40109454; PMCID: PMC11914005. 2: Parkhill M, Salmaso N, D'Angiulli A, Lee V, Aguilar-Valles A. Emerging autism and Fragile X syndrome treatments. Trends Pharmacol Sci. 2025 Mar 17:S0165-6147(25)00024-0. doi: 10.1016/j.tips.2025.02.004. Epub ahead of print. PMID: 40102109. 3: Xue Z, Liu X, Liu Q, Yang X, Yu L. A disproportionality analysis of adverse events associated with loop diuretics in the FDA Adverse Event Reporting System (FAERS). BMC Pharmacol Toxicol. 2025 Mar 17;26(1):63. doi: 10.1186/s40360-025-00890-7. PMID: 40098168. 4: Qi C, Wang Y, Li X, Zheng C, Gu Y, Hu J, Qiu Y, Xie G, Xu S, Zheng Y, Lv Z, Zheng W. Target inhibition of SPAK in choroid plexus attenuates T cell infiltration and demyelination in experimental autoimmune encephalomyelitis. J Neuroinflammation. 2025 Mar 13;22(1):80. doi: 10.1186/s12974-025-03407-5. PMID: 40082912; PMCID: PMC11907836. 5: Julie AOJ, Bébé NO, Sandrine MNY, Emmanuel OP, Antoine KK, Dupon AAB, Cicilien NPQ, Emmanuel NNF, Laure NJ, Claude BD, Désiré DDP. Phytochemical, In Silico, In Vitro, and In Vivo Research on Piptadeniastrum africanum (Fabaceae) Unveiling Anti-Stereotypic, Anxiolytic, and Analgesic Effects in a Sodium Valproate-Induced Autistic Disorders Model. Brain Behav. 2025 Mar;15(3):e70408. doi: 10.1002/brb3.70408. PMID: 40079500; PMCID: PMC11904952. 6: Ambrosy AP, Bensimhon D, Bernstein G, Kolski B, Neutel J, Lala A, Kapur NK, Esque B, Adler E. Correction to: Randomized Study Comparing a Novel Intranasal Formulation of Bumetanide to Oral and Intravenous Formulations. Circulation. 2025 Mar 11;151(10):e708. doi: 10.1161/CIR.0000000000001317. Epub 2025 Mar 10. Erratum for: Circulation. 2025 Mar 11;151(10):737-740. doi: 10.1161/CIRCULATIONAHA.124.072949. PMID: 40063725. 7: Matsushima T, Toji N, Wada K, Shikanai H, Izumi T. Embryonic exposure to valproic acid and neonicotinoid deteriorates the hyperpolarizing GABA shift and impairs long-term potentiation of excitatory transmission in the local circuit of intermediate medial mesopallium of chick telencephalon. Cereb Cortex. 2025 Feb 5;35(2):bhaf044. doi: 10.1093/cercor/bhaf044. PMID: 40037548. 8: Pizzamiglio L, Capitano F, Rusina E, Fossati G, Menna E, Léna I, Antonucci F, Mantegazza M. Neurodevelopmental defects in Dravet syndrome Scn1a+/- mice: Targeting GABA-switch rescues behavioral dysfunctions but not seizures and mortality. Neurobiol Dis. 2025 Apr;207:106853. doi: 10.1016/j.nbd.2025.106853. Epub 2025 Feb 26. PMID: 40021096. 9: Caccialupi Da Prato L, Rezzag Lebza A, Consumi A, Tessier M, Srinivasan A, Rivera C, Laurin J, Pellegrino C. Ectopic expression of the cation-chloride cotransporter KCC2 in blood exosomes as a biomarker for functional rehabilitation. Front Mol Neurosci. 2025 Feb 5;18:1522571. doi: 10.3389/fnmol.2025.1522571. PMID: 39974187; PMCID: PMC11835807. 10: Chen Y, Bi K, Zhang C, Gu J, Yu Z, Lu J, Yu L. Identification of endoplasmic reticulum stress and mitochondrial dysfunction related biomarkers in osteoporosis. Hereditas. 2025 Feb 14;162(1):21. doi: 10.1186/s41065-025-00387-7. PMID: 39953608; PMCID: PMC11827247. 11: Yu X, Cao Y, Mao C, Tao C, Chen W. Association Between Genetically Proxied SLC12A2 Inhibition and Inflammatory Bowel Disease: A Mendelian Randomization Study. Biochem Genet. 2025 Feb 6. doi: 10.1007/s10528-025-11037-y. Epub ahead of print. PMID: 39913044. 12: Zhao Y, Vidossich P, Forbush B, Ma J, Rinehart J, De Vivo M, Cao E. Structural basis for human NKCC1 inhibition by loop diuretic drugs. EMBO J. 2025 Mar;44(5):1540-1562. doi: 10.1038/s44318-025-00368-6. Epub 2025 Jan 28. PMID: 39875725; PMCID: PMC11876703. 13: Radji C, Barrault C, Flausse R, Leveziel N, Cantereau A, Bur C, Terrasse G, Becq F. Modeling ocular surface ion and water transport by generation of lipid- and mucin-producing human meibomian gland and conjunctival epithelial cells. Am J Physiol Cell Physiol. 2025 Mar 1;328(3):C856-C871. doi: 10.1152/ajpcell.00560.2024. Epub 2025 Jan 27. PMID: 39870373. 14: Hawken N, Falissard B, Choquet C, Francois C, Tardu J, Schmid R. Exit interviews from two randomised placebo-controlled phase 3 studies with caregivers of young children with autism spectrum disorder. Front Child Adolesc Psychiatry. 2024 Jun 5;3:1236340. doi: 10.3389/frcha.2024.1236340. PMID: 39816573; PMCID: PMC11731980. 15: Henderson SW, Nourmohammadi S, Hrmova M. Protein Structural Modeling and Transport Thermodynamics Reveal That Plant Cation-Chloride Cotransporters Mediate Potassium-Chloride Symport. Int J Mol Sci. 2024 Dec 2;25(23):12955. doi: 10.3390/ijms252312955. PMID: 39684666; PMCID: PMC11641049. 16: Kefer E, Gulbis B, Weeks P. Comparison of Urine Output Response of Intravenous Bumetanide and Furosemide in Acute Decompensated Heart Failure: An Observational Analysis. J Cardiovasc Pharmacol. 2025 Mar 1;85(3):233-237. doi: 10.1097/FJC.0000000000001658. PMID: 39636041. 17: Casillas-Espinosa PM, Wong JC, Grabon W, Gonzalez-Ramos A, Mantegazza M, Yilmaz NC, Patel M, Staley K, Sankar R, O'Brien TJ, Akman Ö, Balagura G, Numis AL, Noebels JL, Baulac S, Auvin S, Henshall DC, Galanopoulou AS. WONOEP appraisal: Targeted therapy development for early onset epilepsies. Epilepsia. 2025 Feb;66(2):328-340. doi: 10.1111/epi.18187. Epub 2024 Nov 19. PMID: 39560633; PMCID: PMC11922076. 18: Ambrosy AP, Bensimhon D, Bernstein G, Kolski B, Neutel J, Lala A, Kapur NK, Esque B, Adler E. Randomized Study Comparing a Novel Intranasal Formulation of Bumetanide With Oral and Intravenous Formulations. Circulation. 2025 Mar 11;151(10):737-740. doi: 10.1161/CIRCULATIONAHA.124.072949. Epub 2024 Nov 18. Erratum in: Circulation. 2025 Mar 11;151(10):e708. doi: 10.1161/CIR.0000000000001317. PMID: 39555978. 19: Persico AM, Asta L, Chehbani F, Mirabelli S, Parlatini V, Cortese S, Arango C, Vitiello B. The pediatric psychopharmacology of autism spectrum disorder: A systematic review - Part II: The future. Prog Neuropsychopharmacol Biol Psychiatry. 2025 Jan 10;136:111176. doi: 10.1016/j.pnpbp.2024.111176. Epub 2024 Oct 28. PMID: 39490514. 20: Xu H, He J, Du H, Jing X, Liu X. Evaluation of the Choroid Plexus Epithelium Inflammation TLR4/NF-κB/NKCC1 Signal Pathway Activation in the Development of Hydrocephalus. CNS Neurosci Ther. 2024 Oct;30(10):e70085. doi: 10.1111/cns.70085. PMID: 39450988; PMCID: PMC11503839.

View History

HUN47990

HUN47990